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Introduction
Brevundimonas vesicularis (formerly known as Pseudomonas vesicularis), a non-fermenting Gram-negative bacillus, 1, 2 has been infrequently reported as a pathogen causing hospital-acquired infection. 3e5 Most cases of B. vesicularis infection are community-acquired. 4 ,6e11 B. vesicularis can be isolated from the human endocervix, natural soil environments, bottled water, and hospital environments including shower hoses, dental unit reservoirs and hydrotherapy pools.
12e15 B. vesicularis can cause arthritis, endocarditis, meningitis, peritonitis, and primary bloodstream infection in immunocompromised as well as immunocompetent patients. 3e11 Whether B. vesicularis causes severe morbidity or mortality remains unclear.
In this report, 22 cases of B. vesicularis primary bacteremia were identified in a tertiary-care hospital in southern Taiwan between 2006 and 2009. Trends of increasing number of episodes, diversity, and prognosis of B. vesicularis primary bacteremia were observed.
Materials and methods

Study design
From January 2006 to December 2009, the database of the Clinical Microbiology Laboratory of Chi-Mei Medical Center was reviewed to identify bacterial cultures from blood specimens positive for B. vesicularis at the 1330-bed tertiary-care hospital, which serves two million people in southern Taiwan. This study was approved by the institutional review board of Chi-Mei hospital (IRB No. 10006-007). A patient was considered to have B. vesicularis bacteremia when the bacteria was isolated from one or more separate blood cultures processed by the BACTEC FX system (Becton Dickinson, Sparks, MD, USA) and the patient presented with compatible clinical symptoms. All patients with manifestations of systemic inflammatory response syndrome (SIRS) were routinely subject to aerobic and anaerobic blood cultures with 7-day incubations before being reported as negative for B. vesicularis. SIRS was defined as a patient meeting any two of the following criteria: body temperature less than 36 C or greater than 38 C, heart rate greater than 90 beats per minute, tachypnea with more than 20 breaths per minute, arterial partial pressure of carbon dioxide less than 32 mmHg, white blood cell count less than 4000 cells/mm 3 (4 x 10 9 cells/L) or greater than 12,000 cells/mm 3 (12 x 10 9 cells/L); or the presence of greater than 10% immature neutrophils (band forms). 16 Patients with positive B. vesicularis bacteremia were included in the study with the exception of patients with polymicrobial bacteremia. Identification of B. vesicularis was performed using the APE 20 NE system (bioMérieux, Marcy L'etoile, France) or Phoenix-100 ID/AST (Becton Dickinson) automated system. All of the B. vesicularis isolates were tested for minimal inhibitory concentrations (MICs) by the agar dilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). 17 
Definitions
Primary bacteremia was defined as infection not specific to an anatomical site. A nosocomial infection was defined as any episode occurring >48 hours after hospitalization or <14 days after previous discharge. A community-acquired infection was defined as any episode occurring <48 hours after hospitalization or >14 days after previous discharge. Fever was defined as body temperature >37.8 C. The primary outcome was defined as 30-day all-cause mortality and co-morbidities were obtained from medical records. Inappropriate antibiotic therapy was defined as treatment that did not include an antibiotic agent active against B vesicularis, as determined by the in vitro agar dilution method given during the 48 hours after the identification of B. vesicularis.
Statistical analysis
Mean AE standard deviation (SD) was calculated for each continuous variable and percentages were calculated for categorical variables. Categorical variables were evaluated using the Fisher's exact test and continuous variables were evaluated using the ManneWhitney U test. A p value <0.05 was defined as statistically significant. All statistical analyses were performed using version 17 of the Statistical Package for the Social Sciences for Windows (SPSS Inc., Chicago, IL, USA).
Results
A total of 22 patients with B. vesicularis bacteremia were recruited during the study period ( Table 1 ). The ratio of males to females was 0.83. The age of the patients ranged from 3 to 94 years, with an average of 62.7 years; 13.6% (3/22) of patients were younger than 20 years, whereas 50% (11/22) were older than 70 years. Of the 15 patients with underlying chronic illnesses, 31.8% (7/22) had hypertension, 22.7% had prior histories of stroke, and 18.2% (4/22) had malignancies. In total, 13.6% (3/22) of B. vesicularis bacteremia cases were healthcare-associated. The allcause mortality rate was 4.5% (1/22). The only death was a 93-year-old female patient who acquired the bacteremia after admission, presented with shock and then passed away on day 24 of hospitalization. She had been treated with ceftazidime and the isolate from her blood culture was susceptible to ceftazidime [minimal inhibitory concentration (MIC) Z 4 mg/L]. Out of 22 patients, 15 presented with fever at admission and these patients had fewer comorbidities when compared to afebrile patients (1 vs. 2.6, p Z 0.009). Laboratory analysis showed that febrile patients had lower levels of creatinine (1.10 mg/dL vs. Table 2) .
The length of hospital stay averaged 13.3 days for the 19 hospitalized patients (Table 3) . Patients who had 3 or more underlying diseases stayed longer than those who had 2 or less (3.71 days vs. 14.7 days, p Z 0.015). Patients who were initially afebrile had longer hospital stays than those who were febrile (17.6 days vs. 8.2 days, p Z 0.043) ( Table 2) .
Antimicrobial susceptibility tests revealed that 90.9% of B. vesicularis isolates were susceptible to cefpirome, imipenem and piperacillin/tazobactam, 86.4% were susceptible to gentamicin, amikacin and ciprofloxacin, 63.6% were susceptible to ceftazidime and only 59.1% were susceptible to trimethoprim-sulfamethoxazole (Table 4) . 40.9% (9/22) of the patients had been treated with antibiotics for other infections within the previous year; in each case, cephalosporins consisting of cefazolin, cefuroxime and cefpirome were prescribed. However, the antibiogram and length of stay were not statistically different between those who were previously exposed to cephalosporins and those who were not (9.5 days vs. 13.7 days, p Z 0.357) ( Table 3) .
Patients with B. vesicularis bacteremia received diverse antibiotic regimens. Most patients were treated with cephalosporins (12/22, 54.5%) but aminopenicillin with or without beta-lactamase inhibitor (ampicillin or amoxicillinclavulanate), ureidopenicillin (piperacillin) or carbapenem (ertapenem) were also given. Of the 22 patients, 10 (45.5%) received inappropriate initial antibiotic therapy but there was no significant difference in length of hospital stay (11 days vs. 10 days). Most of the patients recovered from the infection and those who did not recover from infection received an intravenous antibiotic regimen (Table 3) .
Discussion
B. vesicularis bacteremia is a clinical challenge for physicians due to a general lack of clinical experience within the medical community. 3e11, 18 In this report, we described 22 cases of B. vesicularis bacteremia with 86.4% of cases being community-acquired. One-third of our patients were well prior to admission, in accordance with previous reports suggesting that B. vesicularis is able to cause invasive infections in healthy persons. However, the majority of patients in this study had chronic diseases such as hypertension, stroke and malignancy. This report indicates that two-thirds of patients presented with fever at admission. Compared to afebrile patients, febrile patients had fewer comorbidities, shorter lengths of hospital stay, and lower levels of creatinine, AST, and ALT. These differences suggest that fever may serve as an important clinical clue for earlier diagnosis, empiric antibiotic therapy, and may contribute to a positive outcome.
This case series also consisted largely of patients with primary bloodstream infection without other associated infectious foci. B. vesicularis was not isolated from urine, sputum or pus specimens which may be explained by a higher rate of blood invasion by B. vesicularis or a reduced ability of the pathogen to compete with other bacterial flora. Further research is needed to clarify this issue. Both the favorable outcome (i.e., only one mortality) and the lack of significant prolonged hospital stays, even for those patients without appropriate initial empirical antibiotic therapy, indicated the low virulence for B. vesicularis.
The antibiotic susceptibility tests of the B. vesicularis isolates revealed that more than 90% were susceptible to cefpirome, piperacillin/tazobactam, and carbapenems, followed by aminoglycosides and ciprofloxacin. By contrast, only 60% of strains were susceptible to ceftazidime and trimethoprim-sulfamethoxazole (Table 4) . A review of literature revealed antibiograms for B. vesicularis conducted only on a single or a few strains based on the KerbyBauer diffusion method without the application of updated CLSI guidelines. 3, 4, 7, 8, 11, 17 Compared with a recently published article, B. vesicularis isolates are 100% sensitive to piperacillin/tazobactam and amikacin but only 27% and 3% sensitive to cefepime and ceftazidime, respectively, based on MICs obtained by the agar dilution method. 19 Therefore, piperacillin/tazobactam, imipenem, and cefpirome are suggested for the treatment of B. vesicularis infection.
Our study had several limitations. The study was retrospective and conducted in a single tertiary hospital serving a population of two million. There were an inadequate number of patients to draw broad conclusions from and no information obtained from long-term care facilities. However, to the best of our knowledge, B. vesicularis infection has been reported only rarely in the published literature. Therefore, we can conclude that B. vesicularis causes community-acquired and low-mortality bloodstream infections, and that the resistance of this microorganism to trimethoprim-sulfamethoxazole and ceftazidime limits the choice of antibiotics for its management.
